Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC.
| Autor: | English IA; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon., Sears RC; Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon. searsr@ohsu.edu.; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.; Brenden Colson Center for Pancreatic Care, Oregon Health and Science University, Portland, Oregon. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer discovery [Cancer Discov] 2020 Apr; Vol. 10 (4), pp. 495-497. |
| DOI: | 10.1158/2159-8290.CD-20-0046 |
| Abstrakt: | In this issue of Cancer Discovery , Sodir and colleagues employ a pancreatic ductal adenocarcinoma mouse model with mutant KRAS and inducible MYC to demonstrate that MYC acts as a reversible driver of malignant tumor progression. Abrogation of MYC triggers rapid regression and disassembly of the ensemble tumor through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms, providing a compelling rationale for therapeutic targeting of MYC. See related article by Sodir et al., p. 588 . (©2020 American Association for Cancer Research.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|